Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

ISSN： 1479-6694

Source： Future Oncology, Vol.1, Iss.6, 2005-12, pp. : 719-731

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

By Karp Judith Lancet Jeffrey

Cancer Investigation, Vol. 25, Iss. 6, 2007-09 ,pp. : 484-494

Informa Healthcare

Access to resources Recommend Favorite

HEMATOLOGIC MALIGNANCIES

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 33-47

Informa Healthcare

Access to resources Recommend Favorite

Current status of molecular targeted therapy for hematologic malignancies: introduction

By Ueda Takanori

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite

The Use of Molecular Markers in Farnesyltransferase Inhibitor (FTI) Therapy of Breast Cancer

By Moasser M.M.

Breast Cancer Research and Treatment, Vol. 73, Iss. 2, 2002-05 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies

By Pimentel Agustin Velez Michel Barahona Luz J Swords Ronan Lekakis Lazaros

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 681-697

Future Medicine

Access to resources Recommend Favorite